{"annotatable":{"parts":["s1v1","s2v1","s3v1","s4v1","s5v1","s6v1","s7v1"]},"anncomplete":true,"sources":[],"metas":{"m_82":{"value":"Low-risk","confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1}},"m_83":{"value":"Low-risk","confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1}},"m_84":{"value":"Low-risk","confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1}},"m_85":{"value":"Low-risk","confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1}},"m_86":{"value":"Some-concerns","confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1}},"m_35":{"value":"Some-concerns","confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1}}},"entities":[{"classId":"e_135","part":"s1v1","offsets":[{"start":1005,"text":"up"}],"coordinates":[],"confidence":{"state":"pre-added","who":["ml:regex"],"prob":0.5},"fields":{},"normalizations":{}},{"classId":"e_135","part":"s1v1","offsets":[{"start":4282,"text":"Up"}],"coordinates":[],"confidence":{"state":"pre-added","who":["ml:regex"],"prob":0.5},"fields":{},"normalizations":{}},{"classId":"e_128","part":"s2v1","offsets":[{"start":377,"text":"the HIFUtherapeutic system used in this clinical trial of breast cancertreatment principally consists of a diagnostic US device, units forcomputer automatic control, six-direction movement, and atherapeutic planning system, a US generator, integrated UStherapy transducers, and a degassed water circulation unit (seeFigure 1)."}],"coordinates":[{"x":"258.80","y":"163.46"},{"x":"83.74","y":"227.75"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_123","part":"s2v1","offsets":[{"start":2034,"text":"an informed consent form was signed byeach patient at the time of enrollment after the principles of HIFUthermal ablation had been completely described"}],"coordinates":[{"x":"139.46","y":"472.09"},{"x":"235.17","y":"496.53"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_109","part":"s2v1","offsets":[{"start":2679,"text":"They were randomised"}],"coordinates":[{"x":"182.21","y":"571.76"},{"x":"267.30","y":"576.24"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_135","part":"s2v1","offsets":[{"start":3023,"text":"up"}],"coordinates":[],"confidence":{"state":"pre-added","who":["ml:regex"],"prob":0.5},"fields":{},"normalizations":{}},{"classId":"e_120","part":"s2v1","offsets":[{"start":5525,"text":"No. of patients 25 23Age (years) 45.571.2 46.571.7Tumour diameter (cm) 3.570.23 (1.8 – 5.6) 3.170.79 (2.0 – 4.7)HistologyInvasive 21 21Noninvasive 4 2Node statusN0 13 12N1 6 5N2 6 6TNMI 2 2II 22 21III 1 0"}],"coordinates":[{"x":"311.36","y":"580.08"},{"x":"507.12","y":"727.33"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_180","part":"s3v1","offsets":[{"start":1560,"text":"nIn the clinical trial, modified radical mastectomy was performed inall of the eligible patients. In all, 23 patients in HIFU groupunderwent the operation within 1 – 2 weeks after the thermalablation. All removed specimens including breast tumour andnormal breast tissue were evaluated by gross and histologicalobservations. They were serially sectioned at approximately 5 mmintervals and the slice thickness was measured."}],"coordinates":[{"x":"130.63","y":"333.60"},{"x":"210.61","y":"414.27"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_158","part":"s3v1","offsets":[{"start":1561,"text":"In the clinical trial, modified radical mastectomy was performed inall of the eligible patients. In all, 23 patients in HIFU groupunderwent the operation within 1 – 2 weeks after the thermalablation. All removed specimens including breast tumour andnormal breast tissue were evaluated by gross and histologicalobservations."}],"coordinates":[{"x":"35.89","y":"349.98"},{"x":"85.23","y":"404.29"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_185","part":"s3v1","offsets":[{"start":1562,"text":"n the clinical trial, modified radical mastectomy was performed inall of the eligible patients."}],"coordinates":[{"x":"38.96","y":"349.98"},{"x":"141.72","y":"364.43"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_191","part":"s3v1","offsets":[{"start":4400,"text":"Two independent observers judged the distribution of thesethree variables and counted the positive cells."}],"coordinates":[{"x":"322.13","y":"170.66"},{"x":"477.10","y":"185.11"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_205","part":"s3v1","offsets":[{"start":4829,"text":"All observed data are displayed as the mean value plus or minusthe standard deviation. The statistical significance of any observeddifference between the mean values of control and treatmentgroups was evaluated using an unpaired Student’s t-test. Thevariability in data was compared with the F test for variance. Thedifferences in percentage data were analysed by using the Fisher’sexact test."}],"coordinates":[{"x":"301.89","y":"269.30"},{"x":"339.42","y":"333.54"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_149","part":"s3v1","offsets":[{"start":5316,"text":"pAmong 23 patients, 16 cases underwent surgery at 7 – 10 days afterHIFU ablation, and the remaining seven patients were operated at11 – 14 days."}],"coordinates":[{"x":"386.51","y":"384.40"},{"x":"346.67","y":"425.21"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_135","part":"s3v1","offsets":[{"start":5317,"text":"Among 23 patients, 16 cases underwent surgery at 7 – 10 days afterHIFU ablation, and the remaining seven patients were operated at11 – 14 days. After HIFU, oedema was noted in the mammary tissuesurrounding the treated tumour. In all cases, the treated areaincluded the tumour and a 1.5 – 2.0 cm margin of normal breasttissue around the tumour."}],"coordinates":[{"x":"301.89","y":"400.83"},{"x":"407.58","y":"455.09"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_149","part":"s3v1","offsets":[{"start":6422,"text":"All treated tumours in the 23 patients were confirmed by grossobservation after removal of the diseased breast."}],"coordinates":[{"x":"301.89","y":"599.09"},{"x":"484.83","y":"613.49"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_205","part":"s3v1","offsets":[{"start":6802,"text":"mean margin of 1.8070.58 cm (range from 1.5 to2.2 cm)"}],"coordinates":[{"x":"358.58","y":"658.84"},{"x":"328.63","y":"673.30"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_205","part":"s4v1","offsets":[{"start":1183,"text":"The percentages of the PCNA labelling index in thenormal breast tissue, breast cancer, and HIFU-treated tumour were6, 44, and 0%. CD44v6-positive cells were present in 56% oftumour samples in the control group (n ¼ 14), and 4.5% of normalbreast tissue (n ¼ 1). But, in the HIFU group, CD44v6-positive cells"}],"coordinates":[{"x":"360.73","y":"688.72"},{"x":"559.38","y":"733.05"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_215","part":"s4v1","offsets":[{"start":1183,"text":"The percentages of the PCNA labelling index in thenormal breast tissue, breast cancer, and HIFU-treated tumour were6, 44, and 0%. CD44v6-positive cells were present in 56% oftumour samples in the control group (n ¼ 14), and 4.5% of normalbreast tissue (n ¼ 1). But, in the HIFU group, CD44v6-positive cells"}],"coordinates":[{"x":"360.73","y":"688.72"},{"x":"559.38","y":"733.05"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_205","part":"s5v1","offsets":[{"start":0,"text":"were not detected within the treated breast cancer (n ¼ 0).CD44v6 þ cell density was significantly higher in tumour than inthe normal breast tissue (Po 0.01), but in the HIFU group theproportion of these membrane-positive cancer cells was 0%.Compared with 60% of MMP-9 within breast cancer in the controlgroup (n ¼ 15), no MMP-9 þ cancer cells were detected in eithernormal breast cancer or treated breast cancer (n ¼ 0), as shown inTable 2"}],"coordinates":[{"x":"35.89","y":"599.03"},{"x":"63.70","y":"673.30"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_120","part":"s5v1","offsets":[{"start":0,"text":"were not detected within the treated breast cancer (n ¼ 0).CD44v6 þ cell density was significantly higher in tumour than inthe normal breast tissue (Po 0.01), but in the HIFU group theproportion of these membrane-positive cancer cells was 0%.Compared with 60% of MMP-9 within breast cancer in the controlgroup (n ¼ 15), no MMP-9 þ cancer cells were detected in eithernormal breast cancer or treated breast cancer (n ¼ 0), as shown inTable 2"}],"coordinates":[{"x":"35.89","y":"599.03"},{"x":"63.70","y":"673.30"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_210","part":"s5v1","offsets":[{"start":5386,"text":"Table 2 Results of immunohistochemical staining in both groupsPCNA labellingindex (%) CD44v6(%) MMP-9(%)Normal breast tissue 6 4.5 0Untreated breast cancer 44 56 60Treated breast cancer 0 0 0"}],"coordinates":[{"x":"35.89","y":"499.71"},{"x":"275.02","y":"566.15"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_205","part":"s5v1","offsets":[{"start":5386,"text":"Table 2 Results of immunohistochemical staining in both groupsPCNA labellingindex (%) CD44v6(%) MMP-9(%)Normal breast tissue 6 4.5 0Untreated breast cancer 44 56 60Treated breast cancer 0 0"}],"coordinates":[{"x":"35.89","y":"499.71"},{"x":"224.17","y":"566.15"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_135","part":"s6v1","offsets":[{"start":4023,"text":"up"}],"coordinates":[],"confidence":{"state":"pre-added","who":["ml:regex"],"prob":0.5},"fields":{},"normalizations":{}}],"relations":[]}